1235406-57-1

Basic information

• Product Name: 5-chloro-N-(2,4-dimethoxybenzyl)-2,4-difluoro-N-(1,3,4-thiadiazol-2-yl)benzenesulfonamide
• Synonyms: 5-chloro-N-(2,4-dimethoxybenzyl)-2,4-difluoro-N-(1,3,4-thiadiazol-2-yl)benzenesulfonamide
• CAS NO: 1235406-57-1
• Molecular Weight: 461.898
• Mol File: 1235406-57-1.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: 5-chloro-N-(2,4-dimethoxybenzyl)-2,4-difluoro-N-(1,3,4-thiadiazol-2-yl)benzenesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: 5-chloro-N-(2,4-dimethoxybenzyl)-2,4-difluoro-N-(1,3,4-thiadiazol-2-yl)benzenesulfonamide(1235406-57-1)
• EPA Substance Registry System: 5-chloro-N-(2,4-dimethoxybenzyl)-2,4-difluoro-N-(1,3,4-thiadiazol-2-yl)benzenesulfonamide(1235406-57-1)

Safety Data

• Hazardous Substances Data: 1235406-57-1(Hazardous Substances Data)

Upstream product

• 613-45-6 2,4-Dimethoxybenzaldehyde 
• 1235406-58-2 N-[(2,4-dimethoxyphenyl)methyl]-1,3,4-thiadiazol-2-amine 
• 13656-57-0 5-chloro-2,4-difluorobenzene-1-sulfonyl chloride 

Downstream Products

• 1354786-72-3 5-Chloro-N-(2,4-dimethoxybenzyl)-2-fluoro-4-[(3-pyridazin-4-ylbiphenyl-4-yl)oxy]-N-1,3,4-thiadiazol-2-ylbenzenesulfonamide 
• 1354786-69-8 5-Chloro-N-(2,4-dimethoxybenzyl)-2-fluoro-4-{[3-pyridazin-4-yl-3'-(trifluoromethyl)biphenyl-4-yl]oxy}-N-1,3,4-thiadiazol-2-ylbenzenesulfonamide 
• 1354786-19-8 5-Chloro-2-fluoro-4-({3-[1-(1-methylazetidin-3-yl)-1H-pyrazol-5-yl]-2'-(trifluoromethyl)biphenyl-4-yl}oxy)-N-1,3,4-thiadiazol-2-ylbenzenesulfonamide 
• 1354786-88-1 4-{[3-(1-azetidin-3-yl-1H-pyrazol-5-yl)-2'-(trifluoromethyl)biphenyl-4-yl]oxy}-5-chloro-2-fluoro-N-1,3,4-thiadiazol-2-ylbenzenesulfonamide 
• 1354786-20-1 5-Chloro-2-fluoro-4-({3-[1-(1-methylazetidin-3-yl)-1H-pyrazol-5-yl]-4'-(trifluoromethyl)biphenyl-4-yl}oxy)-N-1,3,4-thiadiazol-2-ylbenzenesulfonamide 
• 1354786-84-7 4-{[3-(1-azetidin-3-yl-1H-pyrazol-5-yl)-4'-(trifluoromethyl)biphenyl-4-yl]oxy}-5-chloro-2-fluoro-N-1,3,4-thiadiazol-2-ylbenzenesulfonamide 
• 1354786-44-9 4-{[3-(5-Amino-1H-pyrazol-4-yl)-3'-cyanobiphenyl-4-yl]oxy}-5-chloro-2-fluoro-N-(1,3,4-thiadiazol-2-yl)benzenesulfonamide 
• 1354787-01-1 5-Chloro-4-(3'-cyano-3-(3-nitro-1H-pyrazol-4-yl)biphenyl-4-yloxy)-2-fluoro-N-(1,3,4-thiadiazol-2-yl)benzenesulfonamide 
• 1354786-83-6 tert-butyl 3-{5-[4-(2-chloro-4-{[(2,4-dimethoxybenzyl)(1,3,4-thiadiazol-2-yl)amino]sulfonyl}-5-fluorophenoxy)-4'-(trifluoromethyl)biphenyl-3-yl]-1H-pyrazol-1-yl}azetidine-1-carboxylate 
• 1354786-87-0 tert-butyl 3-{5-[4-(2-chloro-4-{[(2,4-dimethoxybenzyl)(1,3,4-thiadiazol-2-yl)amino]sulfonyl}-5-fluorophenoxy)-2'-(trifluoromethyl)biphenyl-3-yl]-1H-pyrazol-1-yl}azetidine-1-carboxylate 
• 1354786-94-9 5-Chloro-4-(2-chloro-5-(pyridazin-4-yl)-3'-(trifluoromethyl)biphenyl-4-yloxy)-N-(2,4-dimethoxybenzyl)-2-fluoro-N-(1,3,4-thiadiazol-2-yl)benzenesulfonamide 
• 1354786-97-2 5-Chloro-4-(4'-chloro-3-(pyridazin-4-yl)-3'-(trifluoromethyl)biphenyl-4-yloxy)-N-(2,4-dimethoxybenzyl)-2-fluoro-N-(1,3,4-thiadiazol-2-yl)benzenesulfonamide 
• 1354786-98-3 5-Chloro-N-(2,4-dimethoxybenzyl)-2-fluoro-4-(2-(pyridazin-4-yl)-4-(6-(trifluoromethyl)pyridin-3-yl)phenoxy)-N-(1,3,4-thiadiazol-2-yl)benzenesulfonamide 
• 1354787-05-5 5-Chloro-4-(2-chloro-3'-fluoro-5-(pyridazin-4-yl)biphenyl-4-yloxy)-N-(2,4-dimethoxybenzyl)-2-fluoro-N-(1,3,4-thiadiazol-2-yl)benzenesulfonamide 

Relevant articles and documents

Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7

A series of acidic diaryl ether heterocyclic sulfonamides that are potent and subtype selective NaV1.7 inhibitors is described. Optimization of early lead matter focused on removal of structural alerts, improving metabolic stability and reducing cytochrome P450 inhibition driven drug-drug interaction concerns to deliver the desired balance of preclinical in vitro properties. Concerns over nonmetabolic routes of clearance, variable clearance in preclinical species, and subsequent low confidence human pharmacokinetic predictions led to the decision to conduct a human microdose study to determine clinical pharmacokinetics. The design strategies and results from preclinical PK and clinical human microdose PK data are described leading to the discovery of the first subtype selective NaV1.7 inhibitor clinical candidate PF-05089771 (34) which binds to a site in the voltage sensing domain.

A 1, 3, 4 - thiadiazole compound and its preparation method (by machine translation)

The invention discloses 2 - (5 - chloro - 2 - fluoro - 4 - (2 - (4 - pyridazinyl) - 4 - (trifluoromethyl) phenoxy) phenyl) sulfonamide - 1, 3, 4 - thiadiazole and its preparation method. 2 - (5 - chloro - 2 - fluoro - 4 - (2 - (4 - pyridazinyl) - 4 - (trifluoromethyl) phenoxy) phenyl) sulfonamide - 1, 3, 4 - thiadiazole of formula (I) structural formula shown, belonging to a new 1, 3, 4 - thiadiazole compounds, has not seen the literature reports, widens the 1, 3, 4 - thiadiazole compounds of the study area, its synthesis yield is high, simple process, and is applicable to industrial production. (by machine translation)

Cycloalkane Derivatives

Disclosed herein are therapeutic agents and/or preventive agents for pain or therapeutic agents and/or preventive agents for a sodium channel associated disease. The present invention provides compounds represented by the following formula (I) or pharmacologically acceptable salts thereof: